glp-1 drugs fda approved for weight loss The U.S. Food and Drug Administration Eli Lilly's pill, the company said, a major milestone the Indianapolis-based drugmaker and one that will test the market for new weight-loss medications GLP-1 Drugs for Weight Loss:

Regulatory bodies are increasingly approving GLP-1 therapies for obesity-specific indications

55 The phase 3 REDEFINE-3 trial will further assess the impact of cagrilinitide/semaglutide on major adverse cardiovascular events in people with obesity (with or without T2DM) and established CVD (clinical trial number NCT05669755

Healthcare professionals should provide comprehensive counselling about realistic expectations, potential side effects, and the importance of lifestyle modifications alongside pharmacotherapy for optimal outcomes in cardiometabolic health

SURMOUNT-3 evaluated the efficacy and safety of tirzepatide compared to placebo for 72 weeks after a 12-week intensive lifestyle intervention lead-in period that included a low-calorie diet and exercise

A study in The New England Journal of Medicine found that just 33% of the dose drove 72% of the weight loss at week 72 with a lower side effect profile

These drugs also improve gonadotropins (LH and FSH), which play a key role in hormone regulation